Search
Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10798ApprovedInvestigationalNeisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalLutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by
Irofulven
go.drugbank.com/drugs/DB05786Investigational” status by the U.S. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.
Stannsoporfin
go.drugbank.com/drugs/DB04912InvestigationalStannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalCiglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. … Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
19-norandrostenedione
go.drugbank.com/drugs/DB01434ExperimentalIllicit19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. … After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalIt is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
R673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning